bluebird bio, Inc. (NASDAQ:BLUE) Shares Bought by Wellington Management Group LLP

Wellington Management Group LLP lifted its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 4.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 582,168 shares of the biotechnology company’s stock after acquiring an additional 26,573 shares during the quarter. Wellington Management Group LLP owned about 0.53% of bluebird bio worth $1,770,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE raised its position in bluebird bio by 885.7% in the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 6,749 shares during the period. Stifel Financial Corp purchased a new stake in shares of bluebird bio during the 3rd quarter valued at about $32,000. Aigen Investment Management LP acquired a new position in bluebird bio during the 3rd quarter worth approximately $34,000. Johnson Investment Counsel Inc. purchased a new position in bluebird bio in the 3rd quarter worth approximately $40,000. Finally, Raymond James & Associates acquired a new stake in bluebird bio in the first quarter valued at approximately $50,000. Institutional investors and hedge funds own 87.43% of the company’s stock.

Analysts Set New Price Targets

BLUE has been the topic of a number of recent research reports. William Blair reissued a “market perform” rating on shares of bluebird bio in a research report on Tuesday, January 9th. Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 price objective on shares of bluebird bio in a research report on Wednesday. Bank of America dropped their target price on bluebird bio from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 21st. Morgan Stanley upgraded bluebird bio from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $3.00 to $7.00 in a research note on Friday, December 8th. Finally, HSBC lowered their price objective on bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. Two analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $5.87.

bluebird bio Stock Up 13.8 %

NASDAQ:BLUE opened at $1.37 on Thursday. bluebird bio, Inc. has a 52 week low of $0.88 and a 52 week high of $5.53. The company has a market cap of $149.25 million, a PE ratio of -1.84 and a beta of 0.75. The business’s 50 day moving average is $1.24 and its two-hundred day moving average is $2.28.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.